Gruss Capital Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Gruss Capital Management’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-330,000	Closed	-$1.14M	–	51
2016 Q1	$1.14M	Hold	330,000	–	–	0.04%	49
2015 Q4	$1.12M	Hold	330,000	–	–	0.04%	76
2015 Q3	$1.72M	Hold	330,000	–	–	0.05%	75
2015 Q2	$2.25M	Hold	330,000	–	–	0.08%	61
2015 Q1	$2.36M	Buy	330,000 +30,000	+10%	+$207K	0.1%	58
2014 Q4	$2.23M	Buy	+300,000	New	+$2.54M	0.06%	71

Other funds holding KIN

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Gruss Capital Management's KIN Position: Q2 2016 in Review

Gruss Capital Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2016, closing a stake of 330,000 shares — an estimated $1.14M sold.

Gruss Capital Management first reported a position in KIN in Q4 2014 and held it in 6 quarters. The position peaked at $2.36M in Q1 2015. 44 funds tracked by Wall St. Rank hold KIN as of Q2 2016.

Gruss Capital Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2016 after selling out during the quarter.
Gruss Capital Management sold 330,000 Kindred Biosciences, Inc. shares in Q2 2016, an estimated $1.14M.
Gruss Capital Management first reported a position in Kindred Biosciences, Inc. in Q4 2014 and held it in 6 quarters.
Gruss Capital Management's Kindred Biosciences, Inc. position peaked at $2.36M in Q1 2015.
44 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2016.

Based on Gruss Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.